According to a new technical market research report, ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS: GLOBAL MARKETS (PHM062A) from BCC Research (www.bccresearch.com), the value of the Alzheimer’s disease market is an estimated $8 billion in 2009, but is expected to increase to $9.6 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 3.7%.
The largest segment of the market, disease-modifying therapeutics, is projected to decrease at a CAGR of -2.6%, dropping to $5.2 billion in 2014, after being valued at nearly $6 billion in 2009.
Diagnostics/biomarkers, the second-largest segment of the market, is estimated at $1.2 billion in 2009, and is expected to increase at a 5-year CAGR of 19.6% to reach nearly $2.9 billion in 2014.
The therapeutics for treatment of symptoms segment is expected to have a 5-year CAGR of 5.1%, with values of $567 million in 2009 and $726 million in 2014.
The smallest segment of the market, imaging products, is projected to have a healthy 5-year CAGR of 18.7%, rising from $361 million in 2009 to $852 million in 2014.
Alzheimer’s disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients increases and the frustration with a lack of effective treatments grows. Though many marketed drugs have been approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, numerous companies are developing novel treatments.
BCC’s key objective was to present a comprehensive analysis of the current pipeline of therapeutic and diagnostic technologies, analyze the market, and outline key factors that will influence the therapeutic area in the next few years.
The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas.
The largest segment of the market, disease-modifying therapeutics, is projected to decrease at a CAGR of -2.6%, dropping to $5.2 billion in 2014, after being valued at nearly $6 billion in 2009.
Diagnostics/biomarkers, the second-largest segment of the market, is estimated at $1.2 billion in 2009, and is expected to increase at a 5-year CAGR of 19.6% to reach nearly $2.9 billion in 2014.
The therapeutics for treatment of symptoms segment is expected to have a 5-year CAGR of 5.1%, with values of $567 million in 2009 and $726 million in 2014.
The smallest segment of the market, imaging products, is projected to have a healthy 5-year CAGR of 18.7%, rising from $361 million in 2009 to $852 million in 2014.
Alzheimer’s disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients increases and the frustration with a lack of effective treatments grows. Though many marketed drugs have been approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, numerous companies are developing novel treatments.
BCC’s key objective was to present a comprehensive analysis of the current pipeline of therapeutic and diagnostic technologies, analyze the market, and outline key factors that will influence the therapeutic area in the next few years.
The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas.
Posts
No comments:
Post a Comment